PrEP Shines at the International AIDS Conference

There were a number of interesting PrEP (pre-exposure prophylaxis) presentations at the International AIDS Conference, which was held in Durban, South Africa, from July 18th to 22nd, 2016. Scott McCallister from Gilead presented 2016 CDC HIV transmission risk data in the U.S., an overview of 32 international studies of FTC/TDF (Truvada) usage for PrEP since it was licensed in the U.S. in 2012, and U.S. PrEP utilization data. Truvada, which is part of a cocktail regimen for people with HIV has demonstrated as much as a 90% effective rate in reducing the risk of HIV transmission when it is taken […]

PrEP for HIV Prevention: Three MSM PrEP trials at IAS 2015 Report on HIV Prevention, Adherence Issues and Intermittent PrEP Dosing Schedules

The bi-annual International AIDS Society’s (IAS) Conference on HIV Pathogenesis was held in Vancouver, Canada from July 19-22, 2015. There were a number of PrEP (Pre-Exposure Prophylaxis) presentations that continue to describe the use of PrEP in MSM.

PrEP for HIV Prevention

Two PrEP trials at CROI show an 86% reduced risk of HIV transmission in MSMs This year’s Conference on Retroviruses and Opportunistic Infections (CROI 2015) was held in Seattle, Washington, from February 23 to 26. Arguably, the most exciting news this year involves three pre-exposure prophylaxis (PrEP) studies.